View in EDS PDF Full Text

The pharmacoepidemiology of antipsychotics for adults with schizophrenia in Canada, 2005 to 2009.

Saved in:
Bibliographic Details
Title: The pharmacoepidemiology of antipsychotics for adults with schizophrenia in Canada, 2005 to 2009.
Authors: Pringsheim T (AUTHOR), Lam D (AUTHOR), Tano DS (AUTHOR), Patten SB (AUTHOR), Pringsheim, Tamara (AUTHOR), Lam, Darren (AUTHOR), Tano, David S (AUTHOR), Patten, Scott B (AUTHOR)
Source: Canadian Journal of Psychiatry. Oct2011, Vol. 56 Issue 10, p630-634. 5p.
Abstract: Objective: To describe the frequency and trends in the use of antipsychotics for adults with schizophrenia in Canada from 2005 to 2009. Methods: Analyses were performed on IMS Brogan's Canadian Disease and Therapeutic Index (CDTI). The CDTI is a national physician panel study consisting of a representative sample of physicians both geographically and by specialty. Weighting adjustments are made to estimate national drug recommendations. Quarterly, panel physicians record all therapeutic recommendations during a 2-day period, including patient age, sex, and indication. Antipsychotic recommendations were estimated using CDTI data in which schizophrenia was listed as the indication. Results: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009, from 329 380 to 454 960 recommendations. There were notable increases in recommendations for chlorpromazine, loxapine, zuclopenthixol, and flupentixol. Second-generation antipsychotic (SGA) recommendations increased to a much lesser extent (9%), which was mostly attributable to an increase in recommendations for clozapine. Drug recommendations for olanzapine decreased by 9%. Conclusion: The rate of increase of FGA use is now greater than that of SGAs. This may be due to data from recent comparative trials, which suggest that clinical efficacy, and the rate of neurological side effects is similar between FGAs and SGAs. The decreasing use of olanzapine may be due to metabolic adverse effects. The increased use of clozapine may be due to data on its superiority in patients who are treatment resistant. [ABSTRACT FROM AUTHOR]
Copyright of Canadian Journal of Psychiatry is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 104590784
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The pharmacoepidemiology of antipsychotics for adults with schizophrenia in Canada, 2005 to 2009.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Pringsheim+T%22">Pringsheim T</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lam+D%22">Lam D</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tano+DS%22">Tano DS</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Patten+SB%22">Patten SB</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pringsheim%2C+Tamara%22">Pringsheim, Tamara</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lam%2C+Darren%22">Lam, Darren</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tano%2C+David+S%22">Tano, David S</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Patten%2C+Scott+B%22">Patten, Scott B</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Canadian+Journal+of+Psychiatry%22">Canadian Journal of Psychiatry</searchLink>. Oct2011, Vol. 56 Issue 10, p630-634. 5p.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Objective: </bold>To describe the frequency and trends in the use of antipsychotics for adults with schizophrenia in Canada from 2005 to 2009. <bold>Methods: </bold>Analyses were performed on IMS Brogan's Canadian Disease and Therapeutic Index (CDTI). The CDTI is a national physician panel study consisting of a representative sample of physicians both geographically and by specialty. Weighting adjustments are made to estimate national drug recommendations. Quarterly, panel physicians record all therapeutic recommendations during a 2-day period, including patient age, sex, and indication. Antipsychotic recommendations were estimated using CDTI data in which schizophrenia was listed as the indication. <bold>Results: </bold>First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009, from 329 380 to 454 960 recommendations. There were notable increases in recommendations for chlorpromazine, loxapine, zuclopenthixol, and flupentixol. Second-generation antipsychotic (SGA) recommendations increased to a much lesser extent (9%), which was mostly attributable to an increase in recommendations for clozapine. Drug recommendations for olanzapine decreased by 9%. <bold>Conclusion: </bold>The rate of increase of FGA use is now greater than that of SGAs. This may be due to data from recent comparative trials, which suggest that clinical efficacy, and the rate of neurological side effects is similar between FGAs and SGAs. The decreasing use of olanzapine may be due to metabolic adverse effects. The increased use of clozapine may be due to data on its superiority in patients who are treatment resistant. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Canadian Journal of Psychiatry is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=104590784
RecordInfo BibRecord:
  BibEntity:
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 5
        StartPage: 630
    Titles:
      – TitleFull: The pharmacoepidemiology of antipsychotics for adults with schizophrenia in Canada, 2005 to 2009.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Pringsheim T
      – PersonEntity:
          Name:
            NameFull: Lam D
      – PersonEntity:
          Name:
            NameFull: Tano DS
      – PersonEntity:
          Name:
            NameFull: Patten SB
      – PersonEntity:
          Name:
            NameFull: Pringsheim, Tamara
      – PersonEntity:
          Name:
            NameFull: Lam, Darren
      – PersonEntity:
          Name:
            NameFull: Tano, David S
      – PersonEntity:
          Name:
            NameFull: Patten, Scott B
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: Oct2011
              Type: published
              Y: 2011
          Identifiers:
            – Type: issn-print
              Value: 07067437
          Numbering:
            – Type: volume
              Value: 56
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: Canadian Journal of Psychiatry
              Type: main
ResultId 1